GlassScriptPhysician profile
William T Hark
NPI 1891708665
$945,272.46
in general payments reported to CMS, 2019-2025
35 companies · $2,668 in 2025
The $2,668 reported for 2025 was more than what 77% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195K · 2020: $4,959 · 2021: $714K · 2022: $24K · 2023: $2,474 · 2024: $2,559 · 2025: $2,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,637 · Education: $64.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,636.57 |
| Education | $64.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $932,154.36 | 2019-2024 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $2,336.97 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,248.04 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,162.86 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $1,100.98 | 2019-2025 | |
| Genentech USA, INC. | $988.96 | 2019-2025 | Xolair |
| Amgen INC. | $879.98 | 2021-2025 | Tezspire |
| Optinose US, INC. | $747.69 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $745.95 | 2020-2025 | |
| Csl Behring | $596.40 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Grifols USA, LLC | $541.64 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $483.90 | 2020-2025 | Takhzyro, Eohilia, Cuvitru |
| Biocryst US Sales Co., LLC | $316.41 | 2021-2025 | Orladeyo |
| Pfizer INC. | $295.40 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $279.32 | 2025 | Neffy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $268.65 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.71 | 2019-2023 | Spiriva Respimat |
| Pharming Healthcare, INC. | $142.67 | 2020-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $131.67 | 2019-2023 | Airduo Digihaler |
| Incyte Corporation | $128.21 | 2022-2024 | Opzelura |
| Aimmune Therapeutics, INC. | $102.99 | 2021-2023 | |
| Alk-Abello, INC | $70.69 | 2019-2022 | |
| Greer Laboratories, INC. | $50.66 | 2021-2024 | Oralair |
| Organon LLC | $50.54 | 2025 | Vtama |
| Covis Pharma Gmbh | $42.94 | 2019 | |
| Azurity Pharmaceuticals, INC. | $42.90 | 2025 | Alvesco |
| Phadia US INC. | $35.26 | 2024 | Immunocap |
| Abbvie INC. | $30.51 | 2022-2023 | |
| Mylan Pharmaceuticals INC. | $25.20 | 2019-2020 | |
| Lilly USA, LLC | $22.14 | 2025 | Ebglyss |
| Sunovion Pharmaceuticals INC. | $20.24 | 2019 | |
| Hikma Pharmaceuticals USA | $15.03 | 2023 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $14.33 | 2021 | |
| Merck Sharp & Dohme LLC | $14.30 | 2023 | |
| Biocryst Pharmaceuticals, INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,096,767.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.